TY - JOUR
T1 - Involvement of gaseous low molecular monoxides in the cutaneous reverse passive Arthus reaction
T2 - Cytoprotective action of carbon monoxide
AU - Shimizu, K.
AU - Bae, S. J.
AU - Hara, T.
AU - Iwata, Y.
AU - Yamaoka, T.
AU - Komura, K.
AU - Muroi, E.
AU - Takenaka, M.
AU - Ogawa, F.
AU - Sato, S.
PY - 2008/8
Y1 - 2008/8
N2 - The deposition of immune complexes (IC) induces an acute inflammatory response with tissue injury, for which the involvement of nitric oxide (NO) and carbon monoxide (CO) has been suggested. NO is induced by NO synthase (NOS) and CO is generated by haeme oxygenase (HO). Among HO isoenzymes, HO-1 is an induced type. To assess the role of NO and CO in the pathogenic process, the cutaneous reverse passive Arthus reaction was examined using NOS inhibitor, HO-1 stimulator and HO-1 inhibitor. To evaluate the reaction we considered oedema, tumour necrosis factor-α, interleukin-6, and neutrophil number. The values of these four parameters were significantly reduced in mice treated with HO-1 stimulator as compared with the positive control mice. Quite the reverse was observed in mice treated with HO-1 inhibitor. These results suggest that the HO-1/CO signalling pathway is a therapeutic target for human IC-mediated disease.
AB - The deposition of immune complexes (IC) induces an acute inflammatory response with tissue injury, for which the involvement of nitric oxide (NO) and carbon monoxide (CO) has been suggested. NO is induced by NO synthase (NOS) and CO is generated by haeme oxygenase (HO). Among HO isoenzymes, HO-1 is an induced type. To assess the role of NO and CO in the pathogenic process, the cutaneous reverse passive Arthus reaction was examined using NOS inhibitor, HO-1 stimulator and HO-1 inhibitor. To evaluate the reaction we considered oedema, tumour necrosis factor-α, interleukin-6, and neutrophil number. The values of these four parameters were significantly reduced in mice treated with HO-1 stimulator as compared with the positive control mice. Quite the reverse was observed in mice treated with HO-1 inhibitor. These results suggest that the HO-1/CO signalling pathway is a therapeutic target for human IC-mediated disease.
UR - http://www.scopus.com/inward/record.url?scp=47249142483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47249142483&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2249.2008.03688.x
DO - 10.1111/j.1365-2249.2008.03688.x
M3 - Article
C2 - 18505425
AN - SCOPUS:47249142483
SN - 0009-9104
VL - 153
SP - 245
EP - 257
JO - Clinical and Experimental Immunology
JF - Clinical and Experimental Immunology
IS - 2
ER -
